8 completed, 1 recruiting. 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Recruiting 1 |
Follow Anesthesia, General: new trials by email Literature Review of Anesthesia, General trials Research Report on Anesthesia, General
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CO2 Modulation in Endovascular Thrombectomy for Acute Ischemic Stroke HYPERCAPNIA, NORMOCAPNIA - Ischemic Stroke, Acute, Thrombectomy | Phase 2 | Recruiting | University Hospital, Clermont-Ferrand | 50 | 2022-07-20 | 2026-09-03 |
| Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children Sugammadex Injection 2mg/kg, Sugammadex Injection 4mg/kg, Sugammadex Injection 8mg/kg - Anesthesia, General, Neuromuscular Blockade | Phase 2 | Completed | Seoul National University Hospital | 32 | 2020-04-29 | 2022-02-10 |
| Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children Sugammadex Injection 2mg/kg, Sugammadex Injection 4mg/kg, Sugammadex Injection 8mg/kg - Anesthesia, General, Neuromuscular Blockade | Phase 2 | Completed | Seoul National University Hospital | 40 | 2019-08-12 | 2022-11-14 |
| A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part A: Japanese Participants (P05956) sugammadex, Placebo - Anesthesia, General | Phase 2 | Completed | Merck Sharp & Dohme LLC | 100 | 2006-01-03 | 2019-03-01 |
| A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957) Sugammadex - Anesthesia, General | Phase 2 | Completed | Merck Sharp & Dohme LLC | 100 | 2005-12-05 | 2019-03-15 |
| A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974) Sugammadex - Anesthesia, General | Phase 2 | Completed | Merck Sharp & Dohme LLC | 102 | 2005-10-04 | 2019-03-05 |
| A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971) Sugammadex, Placebo, Rocuronium - Anesthesia, General | Phase 2 | Completed | Merck Sharp & Dohme LLC | 100 | 2005-09-20 | 2019-11-25 |
| Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024) Sugammadex, Placebo, Esmeron® - Anesthesia, General | Phase 2 | Completed | Merck Sharp & Dohme LLC | 174 | 2004-03-04 | 2019-02-11 |
| Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942) sugammadex, Placebo - Anesthesia, General | Phase 2 | Completed | Merck Sharp & Dohme LLC | 45 | 2003-11-07 | 2017-08-22 |
Ischemic Stroke (1)
Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Nervous System Diseases (1) · Stroke (1) · Vascular Diseases (1)
Sugammadex (8) · Atropine (2) · Neostigmine (2) · Rocuronium (2) · Sodium Chloride (1) · Vecuronium Bromide (1)
Merck Sharp & Dohme LLC (6) · Seoul National University Hospital (2) · University Hospital, Clermont-Ferrand (1)
South Korea (2) · France (1)
Hee-Soo Kim, M.D, Ph.D. (1) · Hee-Soo Kim, M.D., Ph.D. (1) · Russell Chabanne, MD MSc (1)
PMID 17667567, PMID 18648227, PMID 19933538, PMID 20876699, PMID 37124204
2005 (3)